NCT00463814View on ClinicalTrials.gov

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

March 8, 2007

Primary Completion Date

June 17, 2008

Study Completion Date

December 31, 2025

Conditions
TumorCancer
Interventions
DRUG

AZD6244

Participants will receive single oral dose of AZD6244 as described in arm description.

Trial Locations (4)

80045

Research Site, Aurora

6525 GA

Research Site, Nijmegen

3584 CX

Research Site, Utrecht

SM2 5PT

Research Site, Sutton

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY